MOTS-c for Exercise Performance and Metabolic Fitness

Candidate profile

Athletes and fitness enthusiasts seeking improved metabolic efficiency during exercise — particularly endurance athletes, individuals training in caloric deficit, and those with age-related declines in exercise capacity. MOTS-c is most interesting for people whose performance limitation is metabolic (fuel utilization, mitochondrial output) rather than structural (muscle mass, tendon integrity).

Also relevant for individuals with metabolic syndrome or insulin resistance who want to enhance the metabolic response to exercise.

Approach

MOTS-c is a mitochondrial-derived peptide (MDP) — a 16-amino-acid peptide encoded by the mitochondrial genome. It's released into circulation during exercise and appears to function as an exercise-mimetic signal, activating AMPK and improving glucose metabolism independent of insulin signaling.

The rationale: MOTS-c levels decline with age and metabolic disease. Exogenous MOTS-c may restore the metabolic signaling that younger, healthier mitochondria produce naturally — improving glucose uptake into skeletal muscle, enhancing fatty acid oxidation, and supporting mitochondrial biogenesis.

Protocol design

Peptide: MOTS-c, 5–10 mg subcutaneous

Frequency: 3–5 times per week, timed 30–60 minutes before training sessions

Duration: 4–8 weeks

Route: Subcutaneous, abdominal or deltoid

Dosing rationale: The human-equivalent dose extrapolated from rodent studies (5 mg/kg in mice → ~0.4 mg/kg in humans) would suggest 25–30 mg for a 70 kg individual, but the research peptide community has converged on 5–10 mg as a practical dose. The pharmacokinetically optimal dose in humans is not established.

Expected timeline

Week 1: Minimal subjective changes. MOTS-c's effects are metabolic, not immediately perceptible like a stimulant.

Weeks 2–3: Some users report improved exercise endurance — ability to sustain moderate-intensity exercise longer before fatigue. Improved glycemic control after meals (more relevant for insulin-resistant individuals).

Weeks 4–6: Progressive improvement in metabolic markers: fasting glucose, HbA1c (if elevated at baseline), exercise capacity metrics. Body composition changes may emerge — MOTS-c's AMPK activation promotes fatty acid oxidation.

Weeks 6–8: Consolidation of metabolic improvements. Exercise performance gains stabilize.

Concurrent requirements

• Consistent exercise program — MOTS-c enhances the metabolic response to exercise; it does not replace exercise. The peptide and training are synergistic
• Adequate carbohydrate intake — MOTS-c promotes glucose utilization. Extreme low-carb diets may limit its effectiveness
• Sleep and recovery — mitochondrial biogenesis occurs primarily during recovery. Overtraining without recovery negates the cellular adaptation MOTS-c supports

Monitoring

• Performance metrics: Time to exhaustion, power output at lactate threshold, or VO2max testing if available
• Metabolic markers: Fasting glucose, fasting insulin, HOMA-IR (baseline and 4 weeks)
• Body composition: DEXA scan or impedance at baseline and 8 weeks
• Subjective: Training energy rating (1–10), perceived exertion at standard workloads

Limitations

• Human clinical data for MOTS-c is extremely limited — most evidence is rodent and in-vitro
• The optimal dose, timing, and duration in humans are unknown
• MOTS-c is a research peptide without FDA status or standardized production
• Athletic performance is multifactorial — isolating MOTS-c's contribution from training adaptation is difficult
• World Anti-Doping Agency (WADA) status for MOTS-c is unclear — athletes subject to drug testing should verify current prohibited substance lists